Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3950)	1/16/1998 4:41:00 PM
From: biowa	Read Replies (1) \| Respond to of 9719

V1, >>the spinoff funded with VC money may never pay off. yes they kept 55% of the equity buy the VCs put their capital in on a senior (preffered stock basis). The amount of capital was $8m<< The Cytovia spin-off? Did they give any reason why they think that the science for this is any better than the folks already working in apoptosis? Thanks for the detailed reports (and the live Rman sighting). biowa

To: Vector1 who wrote (3950)	1/16/1998 5:05:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9719

How do I put this diplomatically?..... I have a passionate lack of respect for an individual who played an early, determining role in the "science". IMO, this individual was more interested in money than in patients. He/she had the "real estate, biotechnology..... whichever comes first" attitude. Long gone and a millionaire or millionairess several times over, his/her footprints remain. More often than not, corporate cultures are slow to change. In a public corporation that is not governed by critical shareholders, you often encounter the cesspool theory in action..... the really big chunks float to the top. That's the origin of biotech's tainted image.... greed, and a John Q. Public investor that can't discriminate between good science and crud. Disclaimer..... haven't looked at them in a few years, and the culture may very well have changed. I found long ago, however, that (1) they rarely do, and (2) you lose ten good opportunities while researching a single "past stinker". In this age of excellent science mixed with business, why bother? Thanks, V1. Your comments are valuable. Rick